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Adult liver transplantation in the United Kingdom (I): need, indications, patient selection and pre-
transplant medical care. 
 
Abstract 
Chronic or acute liver failure and primary liver cancers can be effectively managed with liver 
transplantation (LT). The range of indications for LT is increasing but there is a mismatch between the 
numbers of available donations and current needs. Specific criteria for the listing of patients exist but, at 
minimum, the predicted mortality without transplantation must exceed that with transplantation, 
coupled with a 50% predicted 5-year survival following LT. The risk posed by liver disease must be 
weighed against the risk of LT considering the patient’s co-morbidities, age, nutritional status and 
behavioural factors in a complex assessment process. This review will focus on current UK practice in the 
selection and care of patients being assessed for liver transplantation.  
 
Key Points and Key Words 
Liver transplantation offers a significant survival benefit for appropriately selected patients 
There is a current mismatch between suitable donor organs and patient needs 
Strict national listing criteria for transplantation for acute and chronic liver disease aim to 
equitably target scarce resources to patients who will gain significant benefit 
A broad range of factors including disease aetiology and severity, psychological, behavioural and 
social factors and nutrition must be considered when offering liver transplantation 
Assessment of patients and care whilst awaiting transplantation is complex and requires 
multidisciplinary input. 
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Liver transplantation (LT) is a lifesaving intervention in acute and chronic liver disease. This article 
reviews the indications, selection process and pre-operative medical care for adult LT recipients in the 
UK. 
LT is indicated in advanced chronic liver disease, fulminant (sub)acute liver failure and primary liver 
cancer. Advanced liver disease has a poor prognosis without transplantation: refractory ascites is 
associated with 50% mortality at 1 year (Moreau et al 2004) and decompensated liver disease has a 
median survival of 2 years and 25% survival at 5 years (D’Amico et al 2006). Survival for adults following 
LT in the UK is 92% at 1 year and 80% at 5 years for elective transplantation and 90% and 80% 
respectively for super-urgent LT (Martin et al 2015) and therefore offers patients a considerable survival 
benefit. However, despite the benefits of LT there is also considerable mortality and morbidity hence 
patient selection is crucial.  
 
Increasing need and limited availability  
LT numbers are rising but the need is increasing more rapidly: 882 LTs were performed in the year to 
2015 between the seven UK centres, rising from fewer than 700 per annum in the mid 2000s. However, 
the number of patients waiting for LT in the UK more than doubled between 2008 and 2015 with over 
500 adult patients currently on the waiting list  (Martin et al 2015). The rise in LT numbers has been 
enabled by increasing use of livers from donors with cardiac death and a minimal increase in donations 
from donors with brain death. Due to the current shortage of suitable donor livers, 2 years after joining 
the list 20% of adult patients will have died or been removed from the waiting list and 4% will still be 
waiting for transplantation (Martin et al 2015). 
Despite the relative scarcity of suitable donations the population requiring LT will continue to grow. 
Liver disease is increasing in prevalence (Williams et al 2014) and there are many patients who may 
benefit from LT who are not currently being assessed. A significant proportion of cirrhotic patients are 
never assessed for transplantation despite this being the treatment that has the potential to offer 
greatest benefit. Many unassessed patients are correctly not referred due to comorbidities or other 
absolute contraindications (CIs), however there is likely a significant unmet need for LT in the UK and the 
scarcity of donations is a major barrier to the transplant programme. 
 
Indications for liver transplantation: 
For LT to be in a patient’s interests predicted survival following LT must exceed that without LT. 
Furthermore, under current UK guidance, patients should have a predicted 5 year survival of >50% to 
ensure maximal utility for each liver transplanted and to avoid patients undergoing complex, major 
surgery with significant associated morbidity for lesser longer term benefit. Registration for LT therefore 
requires patients to meet minimum-listing criteria within four broad indications: acute liver failure (ALF), 
chronic liver disease, variant syndromes and primary liver cancer (see table 1).  
Acute liver failure  
ALF is a syndrome characterised by rapid onset of liver dysfunction with associated coagulopathy and 
encephalopathy. It carries a high risk of mortality and all patients with ALF should be discussed with a 
tertiary liver unit with transplantation facilities. There are specific and unique features to the clinical 
management of ALF (Whitehouse & Wendon, 2013) which should be delivered in an intensive care unit 
environment. The listing criteria differ for ALF due to paracetamol toxicity and non-paracetamol ALF are 
derived from the King’s College Criteria (KCC) (O’Grady et al, 1989). However there are limitations to 
these criteria as some patients die from liver failure despite not meeting these criteria: the sensitivity 
and specificity of the KCC for mortality are 58% and 89% for paracetamol toxicity (McPhail et al 2016) 
and 68% and 82% for non-paracetamol liver failure (McPhail et al 2010) with a NPV of 47-92% (Pauwels 
et al 1993, Anand et al 1997, Dhiman et al 2007, Simpson et al 2009) suggesting that perhaps as few as 
half of patients who die from acute liver failure reach current listing criteria.  
Elective transplantation 
Chronic liver disease: progressive liver disease is associated with deteriorating hepatic synthetic 
function, renal function and sodium homeostasis. These parameters are modelled by the United 
Kingdom End-stage Liver Disease (UKELD) score (see box 1) which was developed from mortality data for 
patients listed for liver transplantation without hepatocellular carcinoma (HCC). A score of >49 predicts 
an annual mortality risk of 9% (Barber et al 2011) which exceeds the 1st year mortality risk of 
undergoing LT hence is used as a threshold for LT listing. 
Despite the UKELD score’s sensitivity for prediction of mortality, many patients with a qualifying UKELD 
score would not benefit from LT. For example patients with established chronic kidney disease may 
achieve a score >49 without intrinsic liver dysfunction. Hence patients with a qualifying UKELD are 
considered for LT only in a suitable clinical setting e.g. with attendant ascites or hepatic encephalopathy. 
Variant syndromes: several clinical scenarios are associated with poor liver-related prognosis or poor 
quality of life and patients may gain benefit from LT independent of their UKELD score (see table 1). 
Common indications are diuretic resistant ascites, chronic hepatic encephalopathy (HE) and recurrent 
cholangitis. The risk-benefit balance of LT for quality of life indications must be carefully considered and 
patients counselled accordingly.  
Hepatocellular carcinoma: LT has a key role in the management of HCC where resection is not possible. 
Various listing criteria meet acceptable mortality outcomes for LT in the setting of HCC and the UK uses 
a modified version of the Milan criteria (see table 1) (Mazzaferro et al 1996) which predict a low risk of 
relapse and death. Current UK outcomes for HCC managed by LT are 68.7% 5-year survival (NHS Blood 
and Transplant 2014) and HCC accounted for 25% of adult LT in the year to March 2014 (Martin et al 
2015). Patients do not need to meet a minimum UKELD score but must have a predicted survival of at 
least 50% at 5 years with LT and not have adverse tumour biology. Downstaging HCC with 
radiofrequency ablation or transarterial (chemo)embolisation to meet criteria for transplantation is 
permitted.  
Selection process 
All patients with cirrhosis or acute liver failure should be considered for transplantation as currently it is 
the intervention that offers the greatest prognostic benefit. However patients with a high predicted risk 
of graft failure, perioperative death or limited 5 year survival are not offered LT. It is imperative that 
patients who may benefit from LT are referred for assessment early. Patients who have absolute CI and 
could not qualify for transplantation should not be referred. Those who are not suitable for LT should be 
considered for referral to palliative care services due to the poor prognosis and high symptom burden of 
advanced liver disease. 
Typically patients referred for LT assessment will be seen by a transplant hepatologist and other 
members of the multidisciplinary team (MDT) for an assessment of their liver disease and comorbidities 
to determine a secure indication for LT and no contra-indications (table 2) and that patients are 
motivated for LT. Common barriers to transplantation can include cardiovascular fitness, poor 
nutritional state and behavioural, drug and alcohol disorders that may need to be assessed by specialists 
prior to further work up (see below).  
Potential candidates undergo a comprehensive multidisciplinary assessment including hepatologists, 
transplant surgeons, specialist nurses in LT, anaesthetists, drug and alcohol services, nutritionists, 
psychologists and specialists from other clinical disciplines where indicated. The assessment typically 
occurs as an inpatient, which has several aims: 
● Identify and optimise factors that may affect patient survival whilst on the waiting list e.g. 
oesophageal varices, viral hepatitis or ascites. 
● Identify predictors of high operative or anaesthetic risk (see linked articles) e.g. cardiac 
dysfunction, pulmonary hypertension, pulmonary dysfunction and poor nutritional status.  
● Screen for contraindications to LT. 
● Allow patients to meet the members of the transplant team and become familiar with the 
transplant unit. 
● Educate patients and their family about the transplantation process, postoperative and long 
term care. 
There is a common set of assessments for most patients (table 3) and others will be tailored to 
individual patient’s needs. Following assessment, each patient is discussed by the transplant MDT and if 
a patient meets listing criteria, will potentially gain benefit from LT and has no absolute 
contraindications they should be put forward for transplantation. 
Patients with acute liver failure are listed on the national super urgent list. The selection process applies 
the same principles as for elective transplantation: a patient must meet minimum listing criteria as 
outlined in table 1, they should have a predicted 5 year survival of more than 50% with transplantation 
and no absolute contraindications.  
Risk assessment 
Drugs and alcohol: due to the link between alcohol and drug dependency and some forms of liver 
disease special consideration regarding these issues is required. A detailed drug and alcohol history 
must be obtained from all patients to inform the aetiology of liver disease, optimise chronic liver disease 
management due to synergistic liver injury, identify other related pathology (e.g. neuropathy, 
cardiomyopathy, occult sepsis), assess social and psychological support and risk factors and identify 
indicators for LT failure.  
Where alcohol was a contributory factor to liver disease or there is a history of illicit drug use patients 
should be assessed by a substance misuse team. Active alcohol consumption following clinical 
recommendation of abstinence, coupled with a clear explanation to the patient the implications of 
continuing to drink against medical advice, is an absolute contraindication to LT. Abstinence may result 
in recompensation of liver disease to the point that LT is no longer required. There is no nationally 
stipulated minimum period of abstinence prior to consideration of transplantation in the UK, but 6 
months abstinence is commonly requested if the patient is able to wait.  
Drug use is linked with liver disease due to the high prevalence of viral hepatitis amongst injecting drug 
users. Patients on stable drug replacement and maintenance therapy can be considered for 
transplantation, but illicit drug use raises considerable concerns. The overriding principles with respect 
to drug and alcohol use relate to the potential for transplant failure. Drug and alcohol dependency raise 
the risk of drug seeking behaviour taking primacy over engagement with health care and concordance 
with post LT treatment such as immunosuppression, represent a risk for recurrent liver disease and a 
potential for harms such as infection from injection practices in the setting of immunosuppression. 
A substance misuse team will advise the transplant MDT of the predicted risk of recidivism and provide 
support and advice for patients regarding long-term strategies to support abstinence and address 
contributing psychological or psychiatric co-morbidities. Patients with a considerable risk of harm from 
ongoing illicit drug use or of a return to harmful alcohol consumption should not be offered LT. 
Age and comorbidities: There are few absolute contraindications to LT (see table 2), however LT should 
only be offered if there is a 5-year predicted survival >50% with LT. Co-morbidities and age may have an 
additive effect on predicted mortality and these factors need to be considered holistically. 
Age: there is no current upper age limit for transplantation in the UK. Some studies demonstrate that 
long-term survival decreases with age above 60 (Collins et al 2000, Malinis et al 2014) mainly due to 
malignancy and infection whereas others found no differences in outcomes for appropriately selected 
older recipients (Bromley et al 1994, Garcia et al 2001, Cross et al 2007, Sonny et al 2015). 
Co-morbidities: common co-morbidities are screened for with particular attention to those associated 
with the aetiology of liver disease, including coronary artery disease, hypertension and type 2 diabetes 
in patients with NAFLD, autoimmune disease in those with immune-mediated liver diseases, 
inflammatory bowel disease and dysplasia in patients with primary sclerosing cholangitis, renal 
dysfunction in viral hepatitis and NAFLD. Co-morbidities should be optimally treated and their impact on 
projected survival following LT be considered cumulatively.  
Malignancy: prior, treated extra-hepatic malignancy is not an absolute contraindication to LT, however 
the risk of recurrence in the setting of long-term immunosuppression needs to be considered for each 
patient with input from an oncologist tailored to that patient and tumour biology. European guidelines 
suggest a 5-year interval from treatment prior to LT would be suitable to exclude recurrence, but there 
is little evidence for this approach (European Association for the Study of the Liver 2016). Patients should 
undergo conventional screening for occult malignancy in line with national screening guidelines with a 
high index of suspicion for, for example, upper GI tract, pulmonary and ENT cancers, in patients with a 
history of alcohol or tobacco addiction. Active cancer, outside primary HCC, epithelioid 
haemangioendothelioma or hepatoblastoma and non-melanoma skin cancer is an absolute 
contraindication to LT.  
Infections: screening for infection with hepatotropic viruses, HIV infection, herpes viruses and 
Toxoplasma is routine. Hepatitis B, C and HIV all have highly effective treatments that are tolerated in 
chronic liver disease and following transplantation and patients should be offered these when 
appropriate. Other latent infections such as TB should be considered and screened for. Active extra-
hepatic sepsis is a contraindication to liver transplantation and the evolution of interval sepsis, including 
spontaneous bacterial peritonitis, will require delay of LT until resolved.  
Smoking: is not a contraindication to LT but patients are strongly encouraged to quit smoking as there is 
evidence of a raised risk of mortality (Leithead et al 2008), malignancy (Watt et al 2009), hepatic 
vascular complications (Pungpapong et al 2002), biliary complications (Mathur et al 2011) and an 
association with relapse to alcohol consumption (Rodrigue et al 2013).  
Nutrition: the evidence for an impact of obesity on LT outcomes is mixed. Some studies demonstrate an 
increase in mortality (Nair et al 2002, Hilingsø et al 2005, Dick et al 2009) whereas others show no 
increase in mortality but more complications including longer length of stay post LT or post-operative 
infections (Hakeem et al 2013, Singhal et al 2015) and others demonstrate no increase in complications 
(Braunfeld et al 1996, Fujikawa et al 2006) with obesity or morbid obesity. However, any mortality risk 
associated with obesity appears lower than the risks of non-transplantation in patients with qualifying 
indications for LT and there is no national upper BMI limit for LT in the UK.   
Malnutrition is common in advanced liver disease and low BMI has a negative impact on outcomes pre- 
and post-LT including survival and length of post-operative recovery (Dick et al 2009, Merli et al 2010, 
DiMartini et al 2013, Ferreira et al 2013, Ney et al 2015). Low BMI is a useful marker of prognosis but 
there remains little evidence of a survival benefit with nutritional interventions (Langer et al 2012) 
although nutritional indices, rate of recovery post LT and other clinical indices are improved with expert 
nutritional intervention (Ferriera et al 2010, Langer et al 2012).  
 
Optimisation 
Many chronic liver disorders and complications of liver disease have effective treatments and care is 
taken to optimise patient’s clinical status whilst on the waiting list. This aims to reduce the risk of LT, 
improve long-term graft function and may lead to improvement to the point where LT is no longer 
required. Table 4 outlines the common diseases and complications of liver disease that should be 
treated prior to LT. 
 
Care whilst on the list 
Whilst a patient is waiting for transplantation they require regular clinical review and assessment to 
monitor their clinical status including screening for de novo HCC or progression of established HCC, 
portal venous thrombosis, pulmonary hypertension and cardiac dysfunction. Progression of liver disease 
may prompt escalation of patient’s position on the waiting list. Specialist support for the psychological 
stresses associated with waiting for LT will be available. Currently each transplant unit identifies their 
priority cases for transplantation based upon clinical liver disease severity and projected mortality. This 
is due to change with the implementation of a national organ allocation process.  
 
Conclusions 
LT offers a significant survival benefit for patients with ALF or chronic liver disease but demand is 
outstripping availability due to the limitations on organ availability and this is predicted to worsen as the 
prevalence of liver disease increases. Patient selection is critical to good patient outcomes and 
comprehensive multidisciplinary care is required to select and optimise patients for the transplant 
programme. Careful consideration of care for those for whom transplantation is not suitable is essential. 
In the following article we will discuss the medical management of patients post-liver transplantation.  
 
Conflicts of interest: 
The authors declare no conflicts of interest. 
 
References 
Anand AC, Nightingale P, Neuberger JM (1997) Early indicators of prognosis in fulminant hepatic failure: 
an assessment of the King's criteria. J Hepatol 26(1):62-8 
Barber K, Madden S, Allen J, Collett D, Neuberger J, Gimson A (2011) Elective Liver Transplant List 
Mortality: Development of a United Kingdom End-Stage Liver Disease Score. Transplantation 92(4): 469-
76 doi: 10.1097/TP.0b013e318225db4d 
Braunfeld MY, Chan S, Pregler J et al (1996) Liver transplantation in the morbidly obese. J Clin Anesth 
8(7):585-90 
Bromley PN, Hilmi I, Tan KC, Williams R, Potter D (1994) Orthotopic liver transplantation in patients over 
60 years old. Transplantation 58(7):800-3 
Collins BH, Pirsch JD, Becker YT et al (2000) Long-term results of liver transplantation in older patients 60 
years of age and older. Transplantation 70(5):780-3 
Cross TJ, Antoniades CG, Muiesan P et al (2007) Liver transplantation in patients over 60 and 65 years: 
an evaluation of long-term outcomes and survival.  Liver Transpl 13(10):1382-8 
D’Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in 
cirrhosis: A systematic review of 118 studies. J Hepatol 44(1): 217-31 
Dhiman RK, Jain S, Maheshwari U et al (2007). Early indicators of prognosis in fulminant hepatic failure: 
an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver 
Transpl 13(6):814-21 
Dick AA, Spitzer AL, Seifert CF et al (2009) Liver transplantation at the extremes of the body mass index. 
Liver Transpl 15(8):968-77. doi: 10.1002/lt.21785 
DiMartini A, Cruz RJ Jr, Dew MA (2013) Muscle mass predicts outcomes following liver transplantation. 
Liver Transpl 19(11):1172-80. doi: 10.1002/lt.23724 
European Association for the Study of the Liver (2016) EASL Clinical Practice Guidelines: Liver 
transplantation. J Hepatol 64(2):433-85 doi:10.1016/j.jhep.2015.10.006 
Ferreira LG, Anastácio LR, Correia MI (2010) The impact of nutrition on cirrhotic patients awaiting liver 
transplantation. Curr Opin Clin Nutr Metab Care 13(5):554-61. doi: 10.1097/MCO.0b013e32833b64d2 
Ferreira LG, Anastácio LR, Lima AS, Touslon Davisson Correia MI (2013) Predictors of mortality in 
patients on the waiting list for liver transplantation. Nutr Hosp 28(3):914-9 
Fujikawa T, Fujita S, Mizuno S et al (2006) Clinical and financial impact of obesity on the outcome of liver 
transplantation. Transplant Proc 38(10):3612-4 
Garcia CE, Garcia RF, Mayer AD, Neuberger J (2001) Liver transplantation in patients over sixty years of 
age. Transplantation 72(4):679-84 
Hakeem AR, Cockbain AJ, Raza SS et al (2013) Increased morbidity in overweight and obese liver 
transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver 
Transpl 19(5):551-62. doi: 10.1002/lt.23618 
Hillingsø JG, Wettergren A, Hyoudo M, Kirkegaard P (2005) Obesity increases mortality in liver 
transplantation--the Danish experience. Transpl Int. 18(11):1231-5 
Langer G, Großmann K, Fleischer S et al (2012) Nutritional interventions for liver-transplanted patients. 
Cochrane Database Syst Rev 15;8:CD007605. doi: 10.1002/14651858.CD007605.pub2 
Leithead JA, Ferguson JW, Hayes PC (2008) Smoking-related morbidity and mortality following liver 
transplantation. Liver Transpl 14(8):1159-64. doi:10.1002/lt.21471 
Malinis MF, Chen S, Allore HG, Quagliarello VJ (2014) Outcomes among older adult liver transplantation 
recipients in the model of end stage liver disease (MELD) era. Ann Transplant 19:478-87 doi: 
10.12659/AOT.890934 
Martin K, Allen E, Johnson R (2015) Annual report on liver transplantation: report for 2014/2015, NHS 
Blood and Transplant, accessed at http://www.odt.nhs.uk/pdf/organ_specific_report_liver_2015.pdf 
Mathur AK, Ranney DN, Patel SP et al (2011) The effect of smoking on biliary complications following 
liver transplantation. Transpl Int 24(1):58-66. doi:10.1111/j.1432-2277.2010.01146.x 
Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small 
hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693-9 
McPhail MJ, Wendon JA, Bernal W (2010) Meta-analysis of performance of Kings's College Hospital 
Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol 53(3):492-9 
doi:10.1016/j.jhep.2010.03.023 
McPhail MJ, Farne H, Senvar N, Wendon JA, Bernal W (2016) Ability of King's College Criteria and Model 
for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-
Analysis. Clin Gastroenterol Hepatol 14(4):516-25 doi: 10.1016/j.cgh.2015.10.007 
Merli M, Giusto M, Gentili F et al (2010) Nutritional status: its influence on the outcome of patients 
undergoing liver transplantation. Liver Int 30(2):208-14. doi: 10.1111/j.1478-3231.2009.02135.x 
Moreau R, Delegue P, Pessione F et al (2004) Clinical characteristics and outcome of patients with 
cirrhosis and refractory ascites. Liver Int 24(5): 457–64 
Nair S, Verma S, Thuluvath PJ (2002) Obesity and its effect on survival in patients undergoing orthotopic 
liver transplantation in the United States. Hepatology 35(1):105-9 
Ney M, Abraldes JG, Ma M et al (2015) Insufficient Protein Intake Is Associated With Increased Mortality 
in 630 Patients With Cirrhosis Awaiting Liver Transplantation. Nutr Clin Pract 30(4):530-6. doi: 
10.1177/0884533614567716 
NHS Blood and Transplant (2015) Liver Transplantation: Selection Criteria and Recipient Registration 
(POL195/4), accessed at http://odt.nhs.uk/pdf/liver_selection_policy.pdf May 2016 
NHS Blood and Transplant (2014) Liver transplantation for hepatocellular carcinoma in the UK – report 
from a national consensus meeting, accessed at 
http://www.odt.nhs.uk/pdf/advisory_group_papers/LAG/HCC_recommendations_IR_TS_b_NAS_Work_
in_Progress.pdf May 2016 
O’Grady JG, Alexander GJ, Hayllar KM, Williams R (1989) Early indicators of prognosis in fulminant 
hepatic failure. Gastroenterology 97(2): 439–45 
Pauwels A, Mostefa-Kara N, Florent C, Lévy VG (1993) Emergency liver transplantation for acute liver 
failure. Evaluation of London and Clichy criteria. J Hepatol 17(1):124-7 
Pungpapong S, Manzarbeitia C, Ortiz J et al (2002) Cigarette smoking is associated with an increased 
incidence of vascular complications after liver transplantation. Liver Transpl 8(7):582-7 
Rodrigue JR, Hanto DW, Curry MP (2013) The Alcohol Relapse Risk Assessment: a scoring system to 
predict the risk of relapse to any alcohol use after liver transplant. Prog Transplant 23(4):310-8. doi: 
10.7182/pit2013604 
Simpson KJ, Bates CM, Henderson NC et al (2009) The utilization of liver transplantation in the 
management of acute liver failure: comparison between acetaminophen and non-acetaminophen 
etiologies. Liver Transpl 15(6):600-9 doi: 10.1002/lt.21681 
Singhal A, Wilson GC, Wima K et al (2015) Impact of recipient morbid obesity on outcomes after liver 
transplantation. Transpl Int 28(2):148-55. doi:10.1111/tri.12483 
Sonny A, Kelly D, Hammel JP, Albeldawi M, Zein N, Cywinski JB (2015) Predictors of poor outcome 
among older liver transplant recipients. Clin Transplant 29(3):197-203. doi: 10.1111/ctr.12500 
Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ (2009) Long-term probability of 
and mortality from de novo malignancy after liver transplantation. Gastroenterology 137(6):2010-7. doi: 
10.1053/j.gastro.2009.08.070 
Whitehouse T, Wendon J (2013) Acute liver failure. Best Pract Res Clin Gastroenterol. 27(5):757-69. doi: 
10.1016/j.bpg.2013.08.010 
Williams R, Ashton K, Aspinall R et al (2014) Implementation of the Lancet Standing Commission on Liver 
Disease in the UK. Lancet 386: 2098-111 doi: 10.1016/S0140-6736(15)00680-7 
UKELD: [(5.395 × ln(INR)) + (1.485 × ln(creatinine)) + (3.13 × ln(bilirubin)) − (81.565 × ln(Na))] + 435 
Box 1: United Kingdom End-stage Liver Disease score formula (Barber et al 2011) 
 
Click here to download Figure (i.e. diagram, illustration, photo)
Adult liver transplantation in the United Kingdom BOX 1.docx
 Transplant 
Category 
Indication Criteria 
Super- 
urgent 
Paracetamol toxicity 
 
 
 
 
 
Acute viral hepatitis / 
cocaine or ecstasy induced 
 
 
Seronegative hepatitis / 
idiosyncratic DILI 
 
 
Acute Wilson’s or Budd-
Chiari syndrome 
 
Post liver transplantation 
 
 
Post total hepatectomy or 
living related donation 
pH<7.25 after 24hrs following fluid resuscitation 
PT>100s/INR>6.5 AND Cr>300µmol/L or anuria AND ≥grade 3 
HE 
Serum lactate >5mmol/L on admission or >4mmol/L after 24hrs 
fluid resuscitation AND HE 
2/3 of point 2 with deterioration 
 
PT>100s/INR>6.5 AND any grade of HE 
Any grade HE and 3 of: age >40, jaundice to HE time of >7 days, 
bilirubin >300µmol/L, PT>50s/INR>3.5 
 
PT>100s/INR>6.5 
INR>2 AND 2 of: age >40, jaundice to HE time of >7 days, 
bilirubin >300µmol/L, PT>50s/INR>3.5 
 
Coagulopathy and any grade of HE 
 
 
Hepatic artery thrombosis <21 days post LT 
Early graft dysfunction 
 
Chronic 
liver 
disease 
Alcoholic liver disease 
NAFLD 
Chronic viral hepatitis 
Autoimmune liver diseases 
Hereditary 
haemachromatosis 
Wilson’s disease 
α-1 antitrypsin deficiency 
Congenital hepatic fibrosis 
UKELD ≥49 
Table Click here to download Table Adult liver transplantation in the
United Kingdom (I) Table 1.docx
(and others) 
2  sclerosing cholangitis 
Variant 
syndromes 
Diuretic resistant ascites 
Chronic HE 
Intractable pruritus 
Hepatopulmonary 
syndrome 
FAP 
Familial 
hypercholesesterolaemia 
Polycystic liver disease 
Hepatic epithelioid 
haemangioendothelioma 
Sickle cell hepatopathy 
TIPS can be considered as an alternative 
With ≥2 admission per year 
Due to cholestatic liver disease 
In the absence of chronic lung disease 
Liver 
tumours 
Hepatocellular carcinoma Single lesion ≤5cm or 
Up to 5 lesions all ≤3cm or 
Single lesion ≤7cm with no evidence of progression or spread 
over 6 months 
No evidence of vascular invasion or distal spread 
PT=prothrombin time, INR = international normalised ratio, Cr=serum creatinine, HE=hepatic encephalopathy, DILI=drug induced liver injury, 
NAFLD=non-alcoholic fatty liver disease, UKELD=United Kingdom End-stage Liver Disease score, TIPS=transjugular intrahepatic portosystemic 
shunt, FAP=familial amyloid polyneuropathy 
Table 1: indications and minimum listing criteria for liver transplantation in the United Kingdom, adapted from POL195/4 
(NHS Blood and Transplant 2015). 
 
 
  
Contraindications to liver transplantation 
Absolute contraindications Failure to meet criteria outlined in table 1 
Acute alcoholic hepatitis (outside of trial setting) 
More than 2 episodes of returning to alcohol use after advice to stop 
Drinking alcohol whilst on LT waiting list (ALD only) 
Ongoing illicit IV drug use 
Recurrent non-adherence to medical care 
Active disseminated malignancy 
Co-morbidities giving <50% predicted 5 year survival with LT 
Severe pulmonary hypertension (non-responsive to medical therapy) 
Relative contraindications Age >65 
Chronic source of infection 
Technical considerations (may include portal venous thrombosis, 
aberrant vascular or biliary anatomy) 
Poor nutritional state (under or overweight) 
Comorbidities including smoking 
Table 2: Relative and absolute contraindications to liver transplantation 
Table Click here to download Table Adult liver transplantation in the
United Kingdom (I) Table 2.docx
 Typical investigations prior to liver transplantation 
General investigations Full history and examination 
Bloods for cross match, full blood count, liver function, renal function, 
coagulation screen, alpha fetoprotein, HIV screen 
Liver aetiology screen  
Electrocardiogram 
Transthoracic echocardiogram with estimated pulmonary artery 
pressures 
Chest X ray 
Pulmonary function tests 
Arterial blood gas analysis 
Formal assessment of glomerular filtration rate 
Oesophagogastroduodenoscopy 
Computed tomography of liver (portal venous and arterial phase 
contrast) 
Cytomegalovirus and toxoplasma screening 
Urine protein:creatinine ratio 
Bone densitometry 
Patient specific 
investigations 
Psychology assessment 
Random blood alcohol and drugs of abuse screen 
Right sided cardiac catheter studies 
Coronary angiogram/myocardial perfusion scan 
Interferon gamma release assay 
Targeted cross sectional imaging 
Liver biopsy 
Colonoscopy 
Cancer screening tests (as per general population) 
Table 3: Investigations required during workup for liver transplantation 
Table Click here to download Table Adult liver transplantation in the
United Kingdom (I) Table 3.docx
  Optimisation strategy Goal 
Primary liver disease   
Alcoholic liver disease Psychological and substance 
misuse services support 
Prevent relapse to drinking 
Develop strategies to maintain 
sobriety 
Autoimmune hepatitis Glucocorticoids and 
immunomodulator therapy 
Control active hepatitis 
Hepatitis B Nucleotide analogue 
therapy 
Suppression of HBVaemia 
Recompensation 
Hepatitis C Direct acting antiviral drugs Clearance of virus 
Prevent recurrence in graft 
NAFLD BP, diabetes and lipid 
control 
Reduce BMI 
Reduce cardiac/anaesthetic 
risks 
Reduce surgical complexity 
HCC Loco-regional therapies Prevent progression of HCC 
outside of LT criteria 
Haemachromatosis Venesection Limit disease progression and 
prevent secondary 
complications 
Wilson’s Disease Chelation therapy Limit disease progression 
Primary Biliary 
Cholangitis 
Ursodeoxycholic acid Optimal disease control 
Primary Sclerosing 
Cholangitis 
Stenting of dominant 
strictures 
Minimise risk of cholangitis and 
obstructive jaundice 
Thrombotic diseases Anticoagulation Prevent clot extension or de 
novo thrombosis 
Table Click here to download Table Adult liver transplantation in the
United Kingdom (I) Table 4.docx
Complications of chronic liver disease  
Hepatocellular 
carcinoma 
6 monthly ultrasound scan, 
MRI liver or triple phase CT 
Consider alpha fetoprotein 
monitoring 
Early identification of  HCC 
Ascites Optimise diuretic regimen 
Consider TIPS 
Reduce risk of spontaneous 
bacterial peritonitis 
Improve nutrition (calorific cost 
of ascites and distension) 
Improve mobility/functional 
reserve 
Varices Beta-blockade 
Variceal band ligation 
Avoid haemorrhage and 
subsequent decompensation 
Malnutrition Specialist assessment 
Nutritional supplements 
NG/NJ feeding 
Improve mobility/functional 
reserve 
Reduce anaesthetic risk 
Improve wound healing 
Hepatic encephalopathy Laxatives 
Rifaximin 
Improve mobility/functional 
reserve and quality of life 
Table 4: Medical strategies to optimise clinical status for patients whilst on the waiting list 
